Rostock, Germany, April 11, 2007 – Bionas GmbH, a specialist for profiling the metabolic activity of cells in vitro, announced that it closed a € 2.1 million financing deal to fund sales, marketing and product expansion. GENIUS Venture Capital GmbH and the KfW-Bankengruppe (ERP-Startfonds) participated in the financing. Additionally, the Federal Ministry of Education and Research, Germany (BMBF) and the Federal State of Mecklenburg-Vorpommern (Ministry of Economics) granted subsidies of undisclosed amounts for two development projects.

“The new funding allows us to expand the sales and marketing of Bionas® analyzing systems throughout Europe and the US,” says Dr. Ralf Ehret, CEO and co-founder of Bionas. “We will also boost technical innovations for novel products and applications to assure the continuous growth of the company.”

The Bionas® 2500 analyzing system, the company´s main product, gives a complete overview of the physiologic state of cells. It can be used to analyze different signal transduction pathways, allowing target validation studies at an early stage in the drug discovery process. Recently, Bionas announced that its device has been selected by Solvay Pharmaceuticals for target validation studies.


About Bionas –
Bionas GmbH, situated in Rostock, Germany, specializes in analyzing systems and services for in-vitro profiling the metabolic activity of cells to understand cellular function.Bionas® 2500 analyzing system measures extracellular acidification, oxygen consumption and cell adhesion in a label-free and non-invasive way and can be applied to various cell types includingprimary cells. The readout is carried out continuously and can be watched online. Main applications include drug profiling, lead optimization, pharmaco kinetics, early toxicology programs, ADME/Tox, chemosensitivity testing, toxicological testing of chemical substances (REACH) and cell culture monitoring/optimization. <

Contact at Bionas GmbH:

Dr. Michael Schulze
Bionas GmbH
Tel.: +49 (0) 381 5196-241
email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:

Dr. Sabine Duntze
b3c communications
Tel.: +49 (0) 861 909 82 20
Email: This email address is being protected from spambots. You need JavaScript enabled to view



Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.